Phenotype-directed clinically driven low-dose direct oral anticoagulant for atrial fibrillation

Area of Science:

• Pharmacology
• Cardiology
• Real-world evidence

Background:

• Clinically-driven dose reduction of direct oral anticoagulants (DOACs) for atrial fibrillation (AF) is prevalent globally.
• Current DOAC dosing is based on landmark trials with highly selected populations, lacking evidence for diverse patient phenotypes.
• There is a significant clinical unmet need for evidence-based guidance on tailoring DOAC doses.

Purpose of the Study:

• To review real-world studies on the efficacy and safety of reduced-dose DOACs.
• To provide evidence for individualized DOAC prescriptions in specific patient phenotypes.
• To address the clinical gap in tailored anticoagulant therapy for atrial fibrillation.

Main Methods:

• Systematic review of real-world studies.
• Analysis of DOAC efficacy and safety data in specific patient subgroups.
• Inclusion of studies on renal and hepatic diseases, elderly, low body weight, Asian populations, and drug-drug interactions.

Main Results:

• Real-world data suggests varying efficacy and safety profiles of reduced-dose DOACs across different patient phenotypes.
• Evidence supports the need for individualized dosing strategies beyond standard recommendations.
• Specific patient groups may benefit from or require dose adjustments for optimal outcomes.

Conclusions:

• Current universal DOAC dosing approaches may not be optimal for all atrial fibrillation patients.
• Individualized DOAC prescriptions, guided by real-world evidence in specific phenotypes, are warranted.
• Further research into tailored anticoagulant therapy can improve patient outcomes and safety.